Teva announces FDA filling acceptance for Ajovy (fremanezumab) in pediatric episodic migraine prevention
Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. announced that the FDA has accepted its supplemental Biologics License Application (sBLA) for Ajovy (fremanezumab-vfrm) to expand the… read more.